Two more centenarians after I M Pei and Herman Wouk:
David Louis Bartholomew (December 24, 1918 – June 23, 2019) was an American musician, bandleader, composer, arranger and record producer, prominent in the music of New Orleans throughout the second half of the 20th century. Originally a trumpeter, he was active in many musical genres, including rhythm and blues, big band, swing music, rock and roll, New Orleans jazz and Dixieland. In his induction into the Rock and Roll Hall of Fame, he was cited as a key figure in the transition from jump blues and swing to R&B and as "one of the Crescent City’s greatest musicians and a true pioneer in the rock and roll revolution."[1]
Many musicians have recorded Bartholomew's songs, but his partnership with Fats Domino produced some of his greatest successes. In the mid-1950s they wrote more than forty hits for Imperial Records, including the Billboard R&B number one chart hit "Ain't That a Shame". Bartholomew's other hit songs as a composer included "I Hear You Knocking", "Blue Monday", "I'm Walkin'", "My Ding-A-Ling", and "One Night". He was a member of the Songwriters Hall of Fame, the Rock and Roll Hall of Fame and the Louisiana Music Hall of Fame.[2]
https://en.wikipedia.org/wiki/Dave_Bartholomew
George Rosenkranz (born György Rosenkranz, August 20, 1916 – 23 June 2019)[3] was a pioneering Mexican scientist in the field of steroid chemistry, who used native Mexican plant sources as raw materials.[4][5] He was born in Hungary, studied in Switzerland and emigrated to the Americas to escape the Nazis, eventually settling in Mexico.[4][6]
At Syntex corporation in Mexico City, Rosenkranz assembled a research group of organic chemists that included future leaders from around the world, such as Carl Djerassi, Luis E. Miramontes and Alejandro Zaffaroni[7][8][9][10][11][12] Revolutionary advances in the understanding of steroid drugs and their production occurred under Dr Rosenkranz's direction.[13] Syntex synthesized a progestin used in some of the first combined oral contraceptive pills and numerous other useful steroids. Under Rosenkranz's leadership, Syntex became "a powerful international force in the development of steroidal pharmaceuticals",[14] and "a pioneer of biotechnology" in the San Francisco Bay Area. Rosenkranz stepped down as CEO in 1982, at the age of 65.[3]
In 2012, he was awarded the Biotechnology Heritage Award, in recognition of his significant contributions to the development of biotechnology through discovery, innovation, and public understanding.[10] He turned 100 in August 2016.[15] Rosenkranz is also an American Contract Bridge League (ACBL) Grand Life Master at his hobby of duplicate bridge, with more than 13,000 masterpoints and 12 NABC titles (below). He has written or co-written more than 10 books on bridge.[16]
Born in Budapest, Hungary, in 1916, Rosenkranz studied chemistry at the Swiss Federal Institute of Technology, where he received his doctorate.[3] His mentor, future Nobel Prize winner Lavoslav Ružička, began Rosenkranz's interest in steroid research. However, Nazi sympathizers were active in Zurich. Ružička shielded Rosenkranz and other Jewish colleagues, but their presence put their mentor at risk. "We got together and we decided to leave Switzerland to protect him," Rosenkranz said in a 2002 article for the Pan American Health Organization's magazine.[6]
Ružička arranged an academic position for Rosenkranz in Quito, Ecuador. While Rosenkranz was waiting in Havana, Cuba for a ship to Ecuador, the Japanese attacked Pearl Harbor. The United States immediately entered World War II. Unable to go to Ecuador, Rosenkranz accepted the Cuban president Fulgencio Batista's offer allowing refugees to stay in the country and work. He found work at the Vieta Plasencia Lab, where he was asked to develop treatments for venereal disease.[5]
The important role of hormones in human health was already known, but ways to synthesize them were unknown. George Rosenkranz's skills as a chemist attracted the interest of Emeric Somlo, a Hungarian immigrant, and Dr. Federico Lehmann at Syntex in Mexico City, Mexico.[17] They had formed the company in 1944 to work with Russell Marker, a Penn State professor, and sought to synthesize the hormone progesterone from diosgenin-containing Mexican yams, which would eventually give rise to the Mexican barbasco trade.[18]:183 After a disagreement Marker left, taking his steroid knowledge with him. Rosenkranz was recruited to replace him, and moved to Mexico City in 1945.[6][7]
Rosenkranz faced the challenge of analyzing Marker's samples to identify their ingredients and reverse engineering Marker's chemical production processes. He didn't have much help: his initial staff included nine lab assistants and only one other chemist,[19] and Mexico lacked a Ph.D. program in chemistry.[20]
When he couldn't find enough fully trained local chemists, Rosenkranz recruited researchers from Mexico and around the world. Rosenkranz also helped to create an institute of chemistry, the Instituto de Quimica (Universidad Nacional Autónoma de México), now considered "a flagship in Mexico's ethnobotanical research".[21] He was able to attract significant synthetic organic chemists as researchers and instructors and to obtain funding to expand programs for the training of organic chemists. He and his colleagues regularly worked at Syntex during the day and then spent the evenings teaching chemistry. Rosenkranz also helped to start the Institute for Molecular Biology in Palo Alto.[20]
Attracting young chemists such as Carl Djerassi, Luis E. Miramontes and Alejandro Zaffaroni was critical to Syntex's first big success.[7][22] The Mayo clinic had reported that the steroid hormone cortisone was an effective anti-inflammatory, capable of relieving painful rheumatoid arthritis symptoms. However, as described by Djerassi, "Until 1951, the only source of cortisone was through an
extraordinarily complex process of 36 different chemical transformations starting from animal bile acids."[23] Several prominent groups of international scientists were attempting to be the first to synthesize cortisone. Rosenkranz's team started working in two shifts, and their dedication paid off. In 1951, Rosenkranz, Djerassi, and their fellow researchers submitted a paper on the synthesis of cortisone, edging out reports from Harvard and Merck by a matter of weeks.[11][24][25][26]
![[Image: 150px-Miramontes_rosenkranz_2001.jpg]](https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Miramontes_rosenkranz_2001.jpg/150px-Miramontes_rosenkranz_2001.jpg)
George Rosenkranz (right) and Luis E. Miramontes (left), 2001 at UNAM, in Mexico City
Having successfully synthesized cortisone, the researchers at Syntex continued to work on the synthesis of progesterone. A female sex hormone, progesterone was used to help pregnant women avoid miscarriages, and to treat infertility.[23] Five months later, under the direction of Rosenkranz and Carl Djerassi, the last step of the synthesis of norethisterone (norethindrone) was successfully completed by Luis E. Miramontes, and Syntex applied for a patent, which was granted as US patent 2,744,122 on May 1, 1956.[6][25][27] Syntex initially reached an agreement with the American company Parke-Davis to market norethisterone as Norlutin for the treatment of gynecological disorders, which was approved by the FDA in 1957.[28] Parke-Davis however refused to develop Syntex's norethisterone as a contraceptive over concerns about a possible Catholic boycott of its other products.[29] This delay placed Syntex at a disadvantage, but by 1962, they had partnered with Johnson & Johnson's Ortho division to introduce the birth control pill Ortho-Novum, which used Syntex's norethisterone.[20][28][30] In March 1964, the FDA approved Syntex's version of Ortho-Novum with the brand name Norinyl (norethisterone 2 mg + mestranol 100 µg).[20][30][31] In March 1964, the FDA also approved Parke-Davis's version of the German company Schering's oral contraceptive Anovlar with the brand name Norlestrin (norethisterone acetate 2.5 mg + ethinylestradiol 50 µg).[31]
Rosenkranz understood the importance of peer recognition, not just commercial success, to the scientists who worked for him. He has said, "To have people work productively, you have to build an intellectually challenging environment, allow creative freedom, and insure peer recognition and respect for the individual."[32] A cascade of papers on steroid chemistry issued from the Rosenkranz lab during the 1940s and 1950s.[11][20] Rosenkranz himself is the author or co-author of over 300 articles in steroid chemistry and is named on over 150 patents.[10]
Rosenkranz gave up his executive positions at Syntex in 1981.[10] Although technically retired for over three decades, Rosenkranz is still active in the industry. In 1996, he became a member of the board of Digital Gene Technologies[33] He is also president of the advisory board of ICT Mexicana.[32]
https://en.wikipedia.org/wiki/George_Rosenkranz
David Louis Bartholomew (December 24, 1918 – June 23, 2019) was an American musician, bandleader, composer, arranger and record producer, prominent in the music of New Orleans throughout the second half of the 20th century. Originally a trumpeter, he was active in many musical genres, including rhythm and blues, big band, swing music, rock and roll, New Orleans jazz and Dixieland. In his induction into the Rock and Roll Hall of Fame, he was cited as a key figure in the transition from jump blues and swing to R&B and as "one of the Crescent City’s greatest musicians and a true pioneer in the rock and roll revolution."[1]
Many musicians have recorded Bartholomew's songs, but his partnership with Fats Domino produced some of his greatest successes. In the mid-1950s they wrote more than forty hits for Imperial Records, including the Billboard R&B number one chart hit "Ain't That a Shame". Bartholomew's other hit songs as a composer included "I Hear You Knocking", "Blue Monday", "I'm Walkin'", "My Ding-A-Ling", and "One Night". He was a member of the Songwriters Hall of Fame, the Rock and Roll Hall of Fame and the Louisiana Music Hall of Fame.[2]
https://en.wikipedia.org/wiki/Dave_Bartholomew
George Rosenkranz (born György Rosenkranz, August 20, 1916 – 23 June 2019)[3] was a pioneering Mexican scientist in the field of steroid chemistry, who used native Mexican plant sources as raw materials.[4][5] He was born in Hungary, studied in Switzerland and emigrated to the Americas to escape the Nazis, eventually settling in Mexico.[4][6]
At Syntex corporation in Mexico City, Rosenkranz assembled a research group of organic chemists that included future leaders from around the world, such as Carl Djerassi, Luis E. Miramontes and Alejandro Zaffaroni[7][8][9][10][11][12] Revolutionary advances in the understanding of steroid drugs and their production occurred under Dr Rosenkranz's direction.[13] Syntex synthesized a progestin used in some of the first combined oral contraceptive pills and numerous other useful steroids. Under Rosenkranz's leadership, Syntex became "a powerful international force in the development of steroidal pharmaceuticals",[14] and "a pioneer of biotechnology" in the San Francisco Bay Area. Rosenkranz stepped down as CEO in 1982, at the age of 65.[3]
In 2012, he was awarded the Biotechnology Heritage Award, in recognition of his significant contributions to the development of biotechnology through discovery, innovation, and public understanding.[10] He turned 100 in August 2016.[15] Rosenkranz is also an American Contract Bridge League (ACBL) Grand Life Master at his hobby of duplicate bridge, with more than 13,000 masterpoints and 12 NABC titles (below). He has written or co-written more than 10 books on bridge.[16]
Born in Budapest, Hungary, in 1916, Rosenkranz studied chemistry at the Swiss Federal Institute of Technology, where he received his doctorate.[3] His mentor, future Nobel Prize winner Lavoslav Ružička, began Rosenkranz's interest in steroid research. However, Nazi sympathizers were active in Zurich. Ružička shielded Rosenkranz and other Jewish colleagues, but their presence put their mentor at risk. "We got together and we decided to leave Switzerland to protect him," Rosenkranz said in a 2002 article for the Pan American Health Organization's magazine.[6]
Ružička arranged an academic position for Rosenkranz in Quito, Ecuador. While Rosenkranz was waiting in Havana, Cuba for a ship to Ecuador, the Japanese attacked Pearl Harbor. The United States immediately entered World War II. Unable to go to Ecuador, Rosenkranz accepted the Cuban president Fulgencio Batista's offer allowing refugees to stay in the country and work. He found work at the Vieta Plasencia Lab, where he was asked to develop treatments for venereal disease.[5]
The important role of hormones in human health was already known, but ways to synthesize them were unknown. George Rosenkranz's skills as a chemist attracted the interest of Emeric Somlo, a Hungarian immigrant, and Dr. Federico Lehmann at Syntex in Mexico City, Mexico.[17] They had formed the company in 1944 to work with Russell Marker, a Penn State professor, and sought to synthesize the hormone progesterone from diosgenin-containing Mexican yams, which would eventually give rise to the Mexican barbasco trade.[18]:183 After a disagreement Marker left, taking his steroid knowledge with him. Rosenkranz was recruited to replace him, and moved to Mexico City in 1945.[6][7]
Rosenkranz faced the challenge of analyzing Marker's samples to identify their ingredients and reverse engineering Marker's chemical production processes. He didn't have much help: his initial staff included nine lab assistants and only one other chemist,[19] and Mexico lacked a Ph.D. program in chemistry.[20]
When he couldn't find enough fully trained local chemists, Rosenkranz recruited researchers from Mexico and around the world. Rosenkranz also helped to create an institute of chemistry, the Instituto de Quimica (Universidad Nacional Autónoma de México), now considered "a flagship in Mexico's ethnobotanical research".[21] He was able to attract significant synthetic organic chemists as researchers and instructors and to obtain funding to expand programs for the training of organic chemists. He and his colleagues regularly worked at Syntex during the day and then spent the evenings teaching chemistry. Rosenkranz also helped to start the Institute for Molecular Biology in Palo Alto.[20]
Attracting young chemists such as Carl Djerassi, Luis E. Miramontes and Alejandro Zaffaroni was critical to Syntex's first big success.[7][22] The Mayo clinic had reported that the steroid hormone cortisone was an effective anti-inflammatory, capable of relieving painful rheumatoid arthritis symptoms. However, as described by Djerassi, "Until 1951, the only source of cortisone was through an
extraordinarily complex process of 36 different chemical transformations starting from animal bile acids."[23] Several prominent groups of international scientists were attempting to be the first to synthesize cortisone. Rosenkranz's team started working in two shifts, and their dedication paid off. In 1951, Rosenkranz, Djerassi, and their fellow researchers submitted a paper on the synthesis of cortisone, edging out reports from Harvard and Merck by a matter of weeks.[11][24][25][26]
![[Image: 150px-Miramontes_rosenkranz_2001.jpg]](https://en.wikipedia.org/wiki/File:Miramontes_rosenkranz_2001.jpg)
George Rosenkranz (right) and Luis E. Miramontes (left), 2001 at UNAM, in Mexico City
Having successfully synthesized cortisone, the researchers at Syntex continued to work on the synthesis of progesterone. A female sex hormone, progesterone was used to help pregnant women avoid miscarriages, and to treat infertility.[23] Five months later, under the direction of Rosenkranz and Carl Djerassi, the last step of the synthesis of norethisterone (norethindrone) was successfully completed by Luis E. Miramontes, and Syntex applied for a patent, which was granted as US patent 2,744,122 on May 1, 1956.[6][25][27] Syntex initially reached an agreement with the American company Parke-Davis to market norethisterone as Norlutin for the treatment of gynecological disorders, which was approved by the FDA in 1957.[28] Parke-Davis however refused to develop Syntex's norethisterone as a contraceptive over concerns about a possible Catholic boycott of its other products.[29] This delay placed Syntex at a disadvantage, but by 1962, they had partnered with Johnson & Johnson's Ortho division to introduce the birth control pill Ortho-Novum, which used Syntex's norethisterone.[20][28][30] In March 1964, the FDA approved Syntex's version of Ortho-Novum with the brand name Norinyl (norethisterone 2 mg + mestranol 100 µg).[20][30][31] In March 1964, the FDA also approved Parke-Davis's version of the German company Schering's oral contraceptive Anovlar with the brand name Norlestrin (norethisterone acetate 2.5 mg + ethinylestradiol 50 µg).[31]
Rosenkranz understood the importance of peer recognition, not just commercial success, to the scientists who worked for him. He has said, "To have people work productively, you have to build an intellectually challenging environment, allow creative freedom, and insure peer recognition and respect for the individual."[32] A cascade of papers on steroid chemistry issued from the Rosenkranz lab during the 1940s and 1950s.[11][20] Rosenkranz himself is the author or co-author of over 300 articles in steroid chemistry and is named on over 150 patents.[10]
Rosenkranz gave up his executive positions at Syntex in 1981.[10] Although technically retired for over three decades, Rosenkranz is still active in the industry. In 1996, he became a member of the board of Digital Gene Technologies[33] He is also president of the advisory board of ICT Mexicana.[32]
https://en.wikipedia.org/wiki/George_Rosenkranz
The ideal subject of totalitarian rule is not the convinced Nazi or the dedicated Communist but instead the people for whom the distinction between fact and fiction, true and false, no longer exists -- Hannah Arendt.